Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome.

Journal

NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 6 2 2024
Statut: ppublish

Résumé

Tetrahydrocannabinol and Cannabidiol in Tourette SyndromeThis randomized controlled crossover trial examined the use of oral tetrahydrocannabinol (THC) with cannabidiol (CBD) to reduce tics in patients with severe Tourette syndrome. Treatment with THC and CBD for 6 weeks led to a significant reduction in tics as measured by the total tic score on the Yale Global Tic Severity Scale, without major adverse effects.

Identifiants

DOI: 10.1056/EVIDoa2300012 PMID: 38320199
pubmed: 38320199
doi: 10.1056/EVIDoa2300012
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

EVIDoa2300012

Auteurs

Philip E Mosley (PE)

Clinical Brain Networks Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Wesley Medical Research Institute, Wesley Hospital, Auchenflower, QLD, Australia.
Queensland Brain Institute, University of Queensland, St. Lucia, QLD, Australia.
Australian eHealth Research Centre, CSIRO Health and Biosecurity, Herston, QLD, Australia.

Lachlan Webb (L)

Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

Anastasia Suraev (A)

The Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Camperdown, NSW, Australia.
School of Psychology, Faculty of Science, University of Sydney, Camperdown, NSW, Australia.

Leah Hingston (L)

Wesley Medical Research Institute, Wesley Hospital, Auchenflower, QLD, Australia.

Tracy Turnbull (T)

Wesley Medical Research Institute, Wesley Hospital, Auchenflower, QLD, Australia.

Kelley Foster (K)

Wesley Medical Research Institute, Wesley Hospital, Auchenflower, QLD, Australia.

Emma Ballard (E)

Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

Lauren Gomes (L)

Queensland Eye Institute, South Brisbane, QLD, Australia.

Adith Mohan (A)

Centre for Healthy Brain Ageing (CHeBA), Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney.
Neuropsychiatric Institute, The Prince of Wales Hospital, Randwick, NSW, Australia.

Perminder S Sachdev (PS)

Centre for Healthy Brain Ageing (CHeBA), Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney.
Neuropsychiatric Institute, The Prince of Wales Hospital, Randwick, NSW, Australia.

Richard Kevin (R)

The Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Camperdown, NSW, Australia.

Rebecca Gordon (R)

The Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Camperdown, NSW, Australia.

Melissa Benson (M)

The Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Camperdown, NSW, Australia.
Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.

Iain S McGregor (IS)

The Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Camperdown, NSW, Australia.
Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.
School of Psychology, Faculty of Science, University of Sydney, Camperdown, NSW, Australia.

Classifications MeSH